Quest Diagnostics stock reports growth as reimbursement risk rises
Article excerpt
Highlighted: the sentence this signal was extracted from
Quest Diagnostics stock stood at USD 233 in after-hours trading on September 23, 2026, down USD 1.76 or 0.75 percent from the prior close. The price was 6.37 percent below the 52-week high of USD 248.84, while market capitalization stood at USD 25.716 billion. Quest Diagnostics reported USD 3.043 billion in revenue for Q2 2026, up 10.2 percent from the year-earlier quarter. Reported EPS reached USD 2.84, compared with USD 2.47 in Q2 2025, according to Yahoo Finance . Reported operating income was USD 459 million, equal to 15.1 percent of revenue, versus USD 438 million and 15.9 percent in the prior-year quarter. The combination shows the central tension in the results: revenue growth accelerated, while the reported operating margin narrowed by 0.8 percentage points. After the first half of fiscal 2026, Quest raised its full-year revenue outlook to USD 11.95 billion to USD 12.05 billion, representing growth of 8.3 percent to 9.2 percent. Reported full-year EPS guidance stands at USD 9.97 to USD 10.17, while adjusted EPS guidance is USD 11.05 to USD 11.25, Yahoo Finance reported. The outlook gives the stock a measurable earnings foundation, but the margin comparison keeps execution in view. Wage inflation and other cost drivers reduced operating income as a share of revenue by 70 basis points in the quarter. A separate policy issue has become relevant for the valuation. The...
Keep reading with a free account
The rest of this article, and every signal for Quest Diagnostics, is in your free account.
